An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus

Meiyan Jiang, Peter Steyger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the sodium-glucose cotransporter-2 (SGLT2; SLC5A2) increases urinary glucose excretion, decreasing plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 have recently become available for clinical therapy of T2DM. Areas covered: The patent claims a new class of SGLT2 inhibitors: derivatives of dioxa-bicyclo[3.2.1]octane-2,3,4-triol (including ertugliflozin; PF-04971729). The invention describes the design, synthesis and pharmacological tests related to ertugliflozin, which could ultimately lead to efficacious therapy for T2DM alone or in combination with other anti-diabetic agents. Expert opinion: Ertugliflozin is likely to be of great clinical significance in the near future. Continued analysis of ertugliflozin derivatives to now validate safe and efficacious treatment of T2DM in a larger number of clinical subjects over an extended period is needed to further support clinical utility. Identification, and discussion, of likely contra-indications is also needed.

Original languageEnglish (US)
Pages (from-to)1349-1352
Number of pages4
JournalExpert Opinion on Therapeutic Patents
Volume25
Issue number11
DOIs
StatePublished - Aug 8 2015

Fingerprint

Type 2 Diabetes Mellitus
Sodium-Glucose Transport Proteins
Pharmacology
Glucose
Expert Testimony
5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
Insulin
Therapeutics

Keywords

  • clinical therapy
  • diabetes
  • dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
  • ertugliflozin
  • inhibitors
  • PF-04971729
  • sodium-glucose linked co-transporter
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. / Jiang, Meiyan; Steyger, Peter.

In: Expert Opinion on Therapeutic Patents, Vol. 25, No. 11, 08.08.2015, p. 1349-1352.

Research output: Contribution to journalArticle

@article{381b2c795de34e9bbe937a2b45122d08,
title = "An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus",
abstract = "Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the sodium-glucose cotransporter-2 (SGLT2; SLC5A2) increases urinary glucose excretion, decreasing plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 have recently become available for clinical therapy of T2DM. Areas covered: The patent claims a new class of SGLT2 inhibitors: derivatives of dioxa-bicyclo[3.2.1]octane-2,3,4-triol (including ertugliflozin; PF-04971729). The invention describes the design, synthesis and pharmacological tests related to ertugliflozin, which could ultimately lead to efficacious therapy for T2DM alone or in combination with other anti-diabetic agents. Expert opinion: Ertugliflozin is likely to be of great clinical significance in the near future. Continued analysis of ertugliflozin derivatives to now validate safe and efficacious treatment of T2DM in a larger number of clinical subjects over an extended period is needed to further support clinical utility. Identification, and discussion, of likely contra-indications is also needed.",
keywords = "clinical therapy, diabetes, dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, ertugliflozin, inhibitors, PF-04971729, sodium-glucose linked co-transporter, type 2 diabetes mellitus",
author = "Meiyan Jiang and Peter Steyger",
year = "2015",
month = "8",
day = "8",
doi = "10.1517/13543776.2015.1076392",
language = "English (US)",
volume = "25",
pages = "1349--1352",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus

AU - Jiang, Meiyan

AU - Steyger, Peter

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the sodium-glucose cotransporter-2 (SGLT2; SLC5A2) increases urinary glucose excretion, decreasing plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 have recently become available for clinical therapy of T2DM. Areas covered: The patent claims a new class of SGLT2 inhibitors: derivatives of dioxa-bicyclo[3.2.1]octane-2,3,4-triol (including ertugliflozin; PF-04971729). The invention describes the design, synthesis and pharmacological tests related to ertugliflozin, which could ultimately lead to efficacious therapy for T2DM alone or in combination with other anti-diabetic agents. Expert opinion: Ertugliflozin is likely to be of great clinical significance in the near future. Continued analysis of ertugliflozin derivatives to now validate safe and efficacious treatment of T2DM in a larger number of clinical subjects over an extended period is needed to further support clinical utility. Identification, and discussion, of likely contra-indications is also needed.

AB - Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the sodium-glucose cotransporter-2 (SGLT2; SLC5A2) increases urinary glucose excretion, decreasing plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 have recently become available for clinical therapy of T2DM. Areas covered: The patent claims a new class of SGLT2 inhibitors: derivatives of dioxa-bicyclo[3.2.1]octane-2,3,4-triol (including ertugliflozin; PF-04971729). The invention describes the design, synthesis and pharmacological tests related to ertugliflozin, which could ultimately lead to efficacious therapy for T2DM alone or in combination with other anti-diabetic agents. Expert opinion: Ertugliflozin is likely to be of great clinical significance in the near future. Continued analysis of ertugliflozin derivatives to now validate safe and efficacious treatment of T2DM in a larger number of clinical subjects over an extended period is needed to further support clinical utility. Identification, and discussion, of likely contra-indications is also needed.

KW - clinical therapy

KW - diabetes

KW - dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

KW - ertugliflozin

KW - inhibitors

KW - PF-04971729

KW - sodium-glucose linked co-transporter

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84947037001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947037001&partnerID=8YFLogxK

U2 - 10.1517/13543776.2015.1076392

DO - 10.1517/13543776.2015.1076392

M3 - Article

VL - 25

SP - 1349

EP - 1352

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 11

ER -